First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma | Naviance

First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma

First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma

A novel treatment approach using combination immunotherapy before and after surgery shows promise for patients with operable mesothelioma, according to a new study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

LEARN MORE

Recent Posts

Blocking Energy Metabolism May Help Treat Aggressive Pediatric Brain Tumor This new drug could change how we treat one of the deadliest cancers Inherited Long Telomeres May Drive Broad Risk for Lymphoid Cancers How a Division I athlete who never smoked turned his stage 4 ALK+ lung cancer diagnosis into a fight for a cure Solving a 15-Year Mystery: Scientists Discover How Gut Bacteria Toxin Invades Colon Cells to Trigger Cancer Advances in Treating Women’s Bladder Cancer Elena’s Story: Recurrent Brain Cancer After a year of turmoil, cancer researchers see promising signs for mRNA vaccines AI and Mammograms